Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 13/20 | 0.65 |
| ▸ | MMP13 | P45452 | 10/20 | 0.65 |
| ▸ | MMP2 | P08253 | 1/20 | 0.65 |
| ▸ | MMP9 | P14780 | 1/20 | 0.65 |
| ▸ | MMP14 | P50281 | 1/20 | 0.65 |
| ▸ | MME | P08473 | 1/20 | 0.59 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.55 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.55 |
| ▸ | PTGIR | P43119 | 2/20 | 0.47 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5613739 | 0.81 | MMP12 (0.74) | MMP12MMP13MMP2MMP9MMP14 | |
| SCHEMBL5613354 | 0.80 | MMP12 (1.00) | MMP12MMP13MMP2MMP9MMP14 | |
| SCHEMBL5613400 | 0.80 | MMP12 (0.76) | MMP12MMP13MMP2MMP9MMP14 | |
| SCHEMBL5613327 | 0.79 | MMP12 (0.74) | MMP12MMP13MMP2MMP9MMP14 | |
| SCHEMBL8325840 | 0.79 | MMP12 (0.74) | MMP12MMP13MMP2MMP9MMP14 | |
| SCHEMBL3466490 | 0.78 | CYP17A1 (0.52) | MMP2MMECYP17A1CYP11B1CYP11B2 | |
| SCHEMBL3466703 | 0.76 | MGLL (0.51) | MMP2MMECYP17A1CYP11B1CYP11B2 | |
| SCHEMBL3786463 | 0.76 | NQO2 (0.73) | CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL5613445 | 0.76 | MMP12 (1.00) | MMP12MMP13MMP2MMP9MMP14 | |
| SCHEMBL5613397 | 0.75 | MMP12 (1.00) | MMP12MMP13MMP2MMP9MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7250439-B2 | Matrix metalloproteinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-07-31 | — | — | US | disclosed |
| US-7250439-B2 | Matrix metalloproteinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-07-31 | — | — | US | disclosed |
| US-7250439-B2 | Matrix metalloproteinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-07-31 | — | — | US | disclosed |
| EP-1654213-B1 | MATRIX METALLOPROTEINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2007-05-23 | — | — | EP | disclosed |
| EP-1654213-B1 | MATRIX METALLOPROTEINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2007-05-23 | — | — | EP | disclosed |
| US-20060160875-A1 | Matrix metalloproteinase inhibitors | GLAXO GROUP LIMITED (GB) | 2006-07-20 | — | — | US | disclosed |
| EP-1654213-A1 | MATRIX METALLOPROTEINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-05-10 | — | — | EP | disclosed |
| WO-2004110974-A1 | MATRIX METALLOPROTEINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004110974-A1 | MATRIX METALLOPROTEINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160875-A1 | Matrix metalloproteinase inhibitors | MMP9, MMP20, MMP10 | MMP12 43/4885MMP13 10/4885MMP2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.